In October 2025, Abbott Laboratories reported third-quarter results showing US$11.37 billion in sales and reaffirmed its 2025 earnings guidance, narrowing expected full-year adjusted diluted EPS to ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

That being said, even among dividend stocks, many aren't worth sticking with for the long term. Let's consider one dividend payer that is: Abbott Laboratories (NYSE: ABT). This healthcare leader has ...

October price plunge is a signal to buy, as analyst and institutional trends suggest they, too, will be buying the stock.

The four new stock additions to the Goldman Sachs Conviction List are outstanding total return ideas for growth and income ...

In the Money with Amber Kanwar is Canada’s top investing podcast. New episodes out Tuesday and Thursday. Subscribe now! ...

Among major gainers, Aurobindo Pharma led the rally, surging 4.49 per cent to Rs 1,118.9, followed by Lupin, which climbed 2.73 per cent to Rs 1,957.6 ...

Find out where the candidates stand on the biggest issues in the Fort Worth area state Senate district. Early voting starts ...

The win is Abbott’s third in a row in federal court in Chicago where hundreds of cases over specialized formulas for preterm ...